Publications

1. Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)

   The National Health Care Insititue has completed its assessment whether pralsetinib (Gavreto®) can be included in the basic ...

   Report | 10-11-2022

2. Progress of the conditional inclusion process for rhPTH 1-84 (Natpar®)

   The National Health Care Institute advises the Director of Pharmaceuticals and Medical Technology at the Ministry of Health, ...

   Report | 02-11-2022

3. GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

   The National Health Care Institute has assessed whether nirmatrelvir/ritonavir (Paxlovid®) can be included in the Medicine ...

   Report | 27-10-2022

4. GVS advice on natalizumab SC (Tysabri®) for adult patients with highly active RRMS

   The National Health Care Institute has completed its assessment whether natalizumab SC (Tysabri®) can be included in the Medicine ...

   Report | 25-10-2022

5. Package advice on ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsing and refractory multiple myeloma (RRMM)

   The National Health Care Institute advises the Minister not to include ciltacabtagene autoleucel (Carvykti®) for the treatment of ...

   Report | 20-10-2022

6. GVS advice to include the relugolix in combination with oestradiol and norethisteronacetate (Ryeqo®) combination

   The National Health Care Institute has completed its assessment whether relugolix in combination with oestradiol and ...

   Report | 19-10-2022

7. Evaluation and reassessment of further conditions for fampridine (Fampyra®)

   The National Health Care Institute advises the Minister that the fampridine (Fampyra®) conditions be revised and that the annual ...

   Report | 17-10-2022

8. Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

   The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...

   Report | 27-09-2022

9. GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection

   The National Health Care Institute advises the Minister to include lenacapavir (Sunlenca®) on List 1B of the Medicine ...

   Report | 22-09-2022

10. Package advice on pegcetacoplan (Aspaveli®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)

    The National Health Care Insititute has completed its assessment whether pegcetacoplan (Aspaveli®) can be included in the basic ...

    Report | 16-09-2022